This company has been acquired
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
MORF Overzicht aandelen
A biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
+ 1 meer risico
Morphic Holding, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$56.99 |
| 52 Week Hoogtepunt | US$57.00 |
| 52 Week Laag | US$19.35 |
| Bèta | 1.49 |
| 11 maand verandering | 1.79% |
| 3 maanden verandering | 94.97% |
| 1 Jaar Verandering | 12.30% |
| 33 jaar verandering | 1.23% |
| 5 jaar verandering | 158.58% |
| Verandering sinds IPO | 216.61% |
Recent nieuws en updates
Recent updates
Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Jun 26
We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 20Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth
Sep 29We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow
Jun 07What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Feb 15We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely
Jan 03What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates
Nov 08Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M
Aug 03Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)
May 06Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)
Mar 01Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
Feb 17We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn
Nov 03Morphic: Pioneering Integrin Medicines
Oct 13Rendement voor aandeelhouders
| MORF | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.2% | 0.6% | 0.8% |
| 1Y | 12.3% | 27.4% | 38.4% |
Rendement versus industrie: MORF matched the US Biotechs industry which returned 12.6% over the past year.
Rendement versus markt: MORF underperformed the US Market which returned 21.7% over the past year.
Prijsvolatiliteit
| MORF volatility | |
|---|---|
| MORF Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: MORF's share price has been volatile over the past 3 months.
Volatiliteit in de loop van de tijd: MORF's weekly volatility has increased from 15% to 23% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2014 | 128 | Praveen Tipirneni | www.morphictx.com |
Morphic Holding, Inc. Samenvatting
| MORF fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.86b |
| Inkomsten(TTM) | -US$179.83m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-15.9x
Koers/WinstverhoudingIs MORF overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MORF resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$165.93m |
| Brutowinst | -US$165.93m |
| Overige uitgaven | US$13.90m |
| Inkomsten | -US$179.83m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.58 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde MORF op de lange termijn?
Bekijk historische prestaties en vergelijking